Showing items 1 - 20 of 61

Your selections:

"Pelvic radiation disease": new understanding and new solutions for a new disease in the era of cancer survivorship

Measuring personal and functional changes in prostate cancer survivors: development and validation of the FADE: data from the TROG 03.04 RADAR trial

The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer

Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial

Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer

Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point

Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy

Radiation induced bowel injury: a neglected problem

The radiotherapeutic injury: a complex 'wound'

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

When to choose radiotherapy for prostate cancer, and what technique?

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials

PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit